3Q 2018 total and OMIDRIA revenues were $4.6 million, compared to $1.7 million in 2Q 2018 and $21.7 million in last years third quarter
Sell-through for October 2018 was 81% of sell-through in October 2017, which was our highest month of OMIDRIA sell-through to date.
The recently released 2019 Outpatient Prospective Payment System (OPPS) final rule for the Centers for Medicare & Medicaid Services
At September 30, 2018, the company had cash, cash equivalents and short-term investments available for operations of $55.2 million. …
[Read on via official release]
Source: US SEC
View full document:
EX-991_of_8-K_for_OMEROS_CORP__8-K-11-08-2018
